# Lycia Therapeutics, Inc. (LYCA): MoatMap facts

As of 27 Oct 2026. Research data, not investment advice.

As of 27 Oct 2026, MoatMap's StockRank for Lycia Therapeutics, Inc. (LYCA) is 10/100, ranked against 24,000+ stocks in 35 markets (Quality 34, Value 23, Momentum 25, each scored against its sector).

- StockRank: 10/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 34, Value 23, Momentum 25: each a 0-100 percentile within Healthcare.
- Position: #23,902 overall, #2,304 in Healthcare.
- Listing: United States, NGM; Healthcare / Biotechnology.
- Last close: 28.85 USD on 26 Oct 2026.
- Insider filings, last 180 days: no director or 5%+ holder trades with a stated value.

Source: https://moatmap.ai/stock/LYCA
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker